Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy:: A prospective randomized placebo-controlled double-blind study
Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy:: A prospective randomized placebo-controlled double-blind study
复制标题
DOI：
10.1111/j.1523-5378.2007.00516.x
复制
发表时间：
2007-08-01
期刊：
影响因子：
4.4
通讯作者：
Unal, Selahattin
中科院分区：
文献类型：
--
作者：
Cindoruk, Mehmet;Erkan, Gulbanu;Unal, Selahattin
背景：最近的研究表明，布氏酵母菌在预防幽门螺杆菌治疗相关的副作用和提高根治率方面具有潜在的作用。我们的目的是研究布氏链球菌在预防与根除幽门螺杆菌相关的副作用方面的有效性和安全性。本研究的第二个目的是确定布氏链霉菌油对根除抗H。材料和方法：124例幽门螺杆菌感染者(男/女：44/80，平均年龄：48±14.25岁)接受了14天的三联疗法(克拉霉素500 mg，tid，阿莫西林1000 mg，tid，兰索拉唑30 mg，tid。)被随机分配到布拉地链霉菌或安慰剂。采用改良格拉斯哥消化不良问卷(GDQ)记录患者的消化不良症状。使用基于症状的问卷调查来评估副作用概况和耐受性。结果：治疗组幽门螺杆菌根除率虽高于对照组，但差异有统计学意义，分别为71%(44/62)和59.7%(37/62)(p>；.05)。治疗组腹泻9例(14.5%)，安慰剂组19例(30.6%)(P<0.05)。
Background: Recent studies indicate a potential role of Saccharomyces boulardii in the prevention of Helicobacter pylori treatment-related side-effects and also in improvement of eradication rate. Our aim is to investigate the efficacy and safety of S. boulardii in the prevention of side-effects related to H. pylori eradication. The secondary aim of the study was to define the effect of S. boulardii oil the eradication success of anti-H. pylori therapy.Materials and methods: one hundred and twenty-four patients with H. pylori infection (male/female: 44/80, mean age: 48 +/- 14.25 year) receiving 14 days of triple therapy (clarithromycin 500 mg b.i.d., amoxicillin 1000 mg b.i.d., and lansoprazole 30 mg b.i.d.) were randomly assigned to S. boulardii or placebo. Dyspeptic symptoms were recorded by using modified Glasgow Dyspepsia Questionnaire (GDQ). Side-effect profile and tolerability were assessed using a symptom-based questionnaire. H. pylori status was rechecked after 6 weeks after completion of eradication therapy.Results: H. pylori eradication rate, although higher in the treatment group, was statistically similar in treatment and control groups: 71 % (44/62) versus 59.7% (37/62), respectively (p >.05). Nine (14.5%) patients in the treatment group and 19 (30.6%) patients in the placebo group experienced diarrhea (p